vs

Side-by-side financial comparison of ACI WORLDWIDE, INC. (ACIW) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.

ACI WORLDWIDE, INC. is the larger business by last-quarter revenue ($481.6M vs $267.3M, roughly 1.8× Ascendis Pharma A/S). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 6.3%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 23.4%).

ACI Worldwide is a digital payments software company headquartered in Elkhorn, Nebraska, that processes billions of transactions daily equating to trillions of U.S. dollars for customers in 94 countries. Banks, financial institutions, merchants, billers, acquirers, issuers, and other third-party payment service providers use its intelligent solutions to deploy secure payment rails across all channels.

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

ACIW vs ASND — Head-to-Head

Bigger by revenue
ACIW
ACIW
1.8× larger
ACIW
$481.6M
$267.3M
ASND
Growing faster (revenue YoY)
ASND
ASND
+36.0% gap
ASND
42.3%
6.3%
ACIW
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
23.4%
ACIW

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACIW
ACIW
ASND
ASND
Revenue
$481.6M
$267.3M
Net Profit
$64.3M
Gross Margin
53.0%
90.5%
Operating Margin
22.6%
Net Margin
13.4%
Revenue YoY
6.3%
42.3%
Net Profit YoY
-34.7%
EPS (diluted)
$0.61

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACIW
ACIW
ASND
ASND
Q4 25
$481.6M
$267.3M
Q3 25
$482.4M
$230.7M
Q2 25
$401.3M
$170.7M
Q1 25
$394.6M
$109.0M
Q4 24
$453.0M
$187.8M
Q3 24
$451.8M
$62.5M
Q2 24
$373.5M
$38.9M
Q1 24
$316.0M
$103.6M
Net Profit
ACIW
ACIW
ASND
ASND
Q4 25
$64.3M
Q3 25
$91.3M
$-65.9M
Q2 25
$12.2M
$-42.0M
Q1 25
$58.9M
$-102.2M
Q4 24
$98.6M
Q3 24
$81.4M
$-107.1M
Q2 24
$30.9M
$-118.1M
Q1 24
$-7.8M
$-141.5M
Gross Margin
ACIW
ACIW
ASND
ASND
Q4 25
53.0%
90.5%
Q3 25
53.7%
89.5%
Q2 25
41.5%
80.1%
Q1 25
45.9%
82.6%
Q4 24
55.8%
91.9%
Q3 24
56.3%
80.6%
Q2 24
45.6%
68.2%
Q1 24
39.5%
92.1%
Operating Margin
ACIW
ACIW
ASND
ASND
Q4 25
22.6%
Q3 25
26.5%
5.1%
Q2 25
8.7%
-33.5%
Q1 25
14.8%
-103.2%
Q4 24
27.0%
Q3 24
27.1%
-167.3%
Q2 24
14.4%
-370.2%
Q1 24
3.0%
-51.2%
Net Margin
ACIW
ACIW
ASND
ASND
Q4 25
13.4%
Q3 25
18.9%
-28.5%
Q2 25
3.0%
-24.6%
Q1 25
14.9%
-93.7%
Q4 24
21.8%
Q3 24
18.0%
-171.5%
Q2 24
8.3%
-303.9%
Q1 24
-2.5%
-136.6%
EPS (diluted)
ACIW
ACIW
ASND
ASND
Q4 25
$0.61
Q3 25
$0.88
Q2 25
$0.12
Q1 25
$0.55
Q4 24
$0.92
Q3 24
$0.77
Q2 24
$0.29
Q1 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACIW
ACIW
ASND
ASND
Cash + ST InvestmentsLiquidity on hand
$196.5M
$665.3M
Total DebtLower is stronger
$817.6M
Stockholders' EquityBook value
$1.5B
$-175.8M
Total Assets
$3.1B
$1.4B
Debt / EquityLower = less leverage
0.54×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACIW
ACIW
ASND
ASND
Q4 25
$196.5M
$665.3M
Q3 25
$199.3M
$582.2M
Q2 25
$189.7M
$533.6M
Q1 25
$230.1M
$559.4M
Q4 24
$216.4M
$604.3M
Q3 24
$177.9M
$675.6M
Q2 24
$157.0M
$279.4M
Q1 24
$183.4M
$345.9M
Total Debt
ACIW
ACIW
ASND
ASND
Q4 25
$817.6M
Q3 25
$867.8M
Q2 25
$898.0M
Q1 25
$845.9M
Q4 24
$924.6M
Q3 24
$994.3M
Q2 24
$1.0B
Q1 24
$1.0B
Stockholders' Equity
ACIW
ACIW
ASND
ASND
Q4 25
$1.5B
$-175.8M
Q3 25
$1.5B
$-188.0M
Q2 25
$1.4B
$-202.6M
Q1 25
$1.5B
$-205.0M
Q4 24
$1.4B
$-114.2M
Q3 24
$1.3B
$-105.1M
Q2 24
$1.2B
$-346.8M
Q1 24
$1.3B
$-257.2M
Total Assets
ACIW
ACIW
ASND
ASND
Q4 25
$3.1B
$1.4B
Q3 25
$3.2B
$1.2B
Q2 25
$3.1B
$1.2B
Q1 25
$3.2B
$1.1B
Q4 24
$3.0B
$1.3B
Q3 24
$3.1B
$1.2B
Q2 24
$3.4B
$819.0M
Q1 24
$3.3B
$866.7M
Debt / Equity
ACIW
ACIW
ASND
ASND
Q4 25
0.54×
Q3 25
0.59×
Q2 25
0.64×
Q1 25
0.57×
Q4 24
0.65×
Q3 24
0.75×
Q2 24
0.82×
Q1 24
0.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACIW
ACIW
ASND
ASND
Operating Cash FlowLast quarter
$121.8M
$58.2M
Free Cash FlowOCF − Capex
$116.6M
FCF MarginFCF / Revenue
24.2%
Capex IntensityCapex / Revenue
1.1%
Cash ConversionOCF / Net Profit
1.89×
TTM Free Cash FlowTrailing 4 quarters
$309.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACIW
ACIW
ASND
ASND
Q4 25
$121.8M
$58.2M
Q3 25
$73.0M
Q2 25
$49.8M
Q1 25
$78.2M
$-15.5M
Q4 24
$126.5M
$-330.7M
Q3 24
$54.0M
Q2 24
$55.0M
Q1 24
$123.2M
$-109.7M
Free Cash Flow
ACIW
ACIW
ASND
ASND
Q4 25
$116.6M
Q3 25
$69.6M
Q2 25
$47.6M
Q1 25
$76.1M
Q4 24
$119.5M
Q3 24
$50.5M
Q2 24
$53.3M
Q1 24
$120.0M
FCF Margin
ACIW
ACIW
ASND
ASND
Q4 25
24.2%
Q3 25
14.4%
Q2 25
11.9%
Q1 25
19.3%
Q4 24
26.4%
Q3 24
11.2%
Q2 24
14.3%
Q1 24
38.0%
Capex Intensity
ACIW
ACIW
ASND
ASND
Q4 25
1.1%
Q3 25
0.7%
Q2 25
0.5%
Q1 25
0.5%
Q4 24
1.5%
Q3 24
0.8%
Q2 24
0.5%
Q1 24
1.0%
Cash Conversion
ACIW
ACIW
ASND
ASND
Q4 25
1.89×
Q3 25
0.80×
Q2 25
4.08×
Q1 25
1.33×
Q4 24
1.28×
Q3 24
0.66×
Q2 24
1.78×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACIW
ACIW

Issuing And Acquiring$183.7M38%
License$158.3M33%
Maintenance$50.8M11%
Software And Platform Service$49.6M10%
Merchant Payments$42.4M9%

ASND
ASND

Segment breakdown not available.

Related Comparisons